Sveriges mest populära poddar

Acute Myeloid Leukemia | Oncology Today with Dr Neil Love: Novel Agents and Strategies in AML (Companion Faculty Lecture)

50 min•17 november 2022

Featuring a slide presentation and related discussion from Dr Eytan Stein, including the following topics:

Historical paradigms for treating newly diagnosed acute myeloid leukemia (AML) (0:00)
Long-term findings and emerging results with venetoclax-based therapies for newly diagnosed and relapsed/refractory (R/R) AML (1:19)
Efficacy and tolerability of oral decitabine/cedazuridine for patients with AML (19:27)
Mechanism of action, activity and safety of magrolimab-based therapies for newly diagnosed and R/R disease (23:34)
Sabatolimab: Mechanism of action and efficacy in combination with a hypomethylating agent (32:01)
Therapeutic targeting of Menin and NPM1 mutations in AML; activity of entospletinib in combination with induction chemotherapy (37:29)

CME information and select publications

Fler avsnitt av Research To Practice | Oncology Videos

Oral SERDs for Breast Cancer | Erica Mayer, MD, MPH, FASCO

30 apr.•29 min

Oral SERDs for Breast Cancer | Aditya Bardia, MD, MPH

30 apr.•28 min

EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

27 apr.•57 min

EGFR-Mutant Non-Small Cell Lung Cancer | Suresh S Ramalingam, MD

27 apr.•26 min

EGFR-Mutant Non-Small Cell Lung Cancer | Helena Yu, MD

27 apr.•30 min

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

25 apr.•17 min

Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances

23 apr.•58 min

Prostate Cancer | Scott T Tagawa, MD, MS

23 apr.•25 min

Prostate Cancer | Andrew J Armstrong, MD, ScM

23 apr.•24 min

Menin Inhibitors in Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances

20 apr.•59 min

Research To Practice | Oncology Videos med Dr Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.